May 2022 Altavant Sciences Presents Data Showing Potential for Combination of Rodatristat Ethyl and Ambrisentan in Model of Pulmonary Arterial Hypertension Learn more
May 2022 Altavant Sciences Presented Data at ISHLT Showing Potency and Distribution of Bronchiolitis Obliterans Candidate, ALTA-2530 Learn more
April 2022 Altavant Sciences to Present Data at ISHLT Showing Potency and Distribution of Bronchiolitis Obliterans Candidate, ALTA-2530 Learn more
April 2022 Enzyvant Announces Plans to Expand Regenerative Medicine Manufacturing Capabilities Learn more
March 2022 Sumitovant and Enzyvant Appoint Bill Symonds, CEO of Altavant Sciences, as Interim Chief Executive Officer of Enzyvant Learn more
October 2021 Enzyvant Receives FDA Approval for RETHYMIC® (allogeneic processed thymus tissue-agdc), a One-Time Regenerative Tissue-Based Therapy for Pediatric Congenital Athymia Learn more
August 2021 Enzyvant Announces Publication of Positive Clinical Data in Pediatric Patients with Congenital Athymia Treated with Investigational RVT-802 (allogeneic processed thymus tissue-agdc) Learn more
August 2021 Enzyvant Announces First-Ever Data on Burden of Illness and Costs of Supportive Care for Pediatric Congenital Athymia Learn more
May 2021 Aceragen Launches with Acquisition of Enzyvant‘s Investigational Therapy for Farber Disease and $35 Million Product Financing with NovaQuest Learn more
April 2021 ENZYVANT Resubmits Biologics Licensing Application (BLA) to FDA for RVT-802 for Pediatric Congenital Athymia Learn more
December 2019 Sumitomo Dainippon Pharma Completes the Formation of the Strategic Alliance with Roivant Sciences Learn more
November 2019 Sumitomo Dainippon Pharma and Roivant Sciences Sign Definitive Agreement for Strategic Alliance Learn more
June 2019 Enzyvant Announces FDA Acceptance of Biologics License Application (BLA) and Priority Review Status for RVT-802, a Novel Investigational Tissue-Based Regenerative Therapy for Pediatric Congenital Athymia Learn more
April 2019 Enzyvant’s Investigational Regenerative Treatment (RVT-802) for Congenital Athymia to be Discussed in Symposium, Platform Presentation and Poster Session at Clinical Immunology Society Meeting Learn more
February 2019 Enzyvant Appoints Industry Veteran Rachelle Jacques as Chief Executive Officer Learn more
July 2018 Enzyvant Announces Initiation of RVT-802 Rolling BLA Submission for the Treatment of Complete DiGeorge Anomaly Learn more